| Title: |
Long-term effects of esaxerenone in patients with type 2 diabetes, diabetic kidney disease, and hypertension (JDDM77). |
| Authors: |
Uchida, Daigaku, Sato, Yasunori, Kanatsuka, Azuma, Kuribayashi, Nobuichi, Nakamura, Susumu, Ko, Shigetake, Maegawa, Hiroshi, Hasegawa, Atsushi, Yamada, Daishiro, Yoshimura, Haruhiko, Yokoyama, Hiroki, Sakai, Kentaro, Kimura, Kenichi, Kudo, Mikihiko, Ishigaki, Yasushi, Yamaguchi, Hiroshi, Okuguchi, Fuminobu, Yano, Nobuki, Seino, Hiroaki, Ajihara, Takashi |
| Source: |
Diabetology International; Jan2025, Vol. 16 Issue 1, p153-161, 9p |
| Abstract: |
Objectives: This clinical study assessed the three-year, long-term effects of esaxerenone, a non-steroidal aldosterone receptor blocker, on Japanese patients with type 2 diabetes, diabetic kidney disease, and hypertension who were receiving renin-angiotensin system inhibitors. Materials and methods: Data from a computerized diabetic care database were used to retrospectively compare esaxerenone users (Group A) with non-esaxerenone users (Group B). Propensity score weighting was applied to Group B. The study primarily focused on percent changes in the Urine Albumin-Creatinine Ratio (UACR) from baseline and also examined the estimated Glomerular Filtration Rate (eGFR), blood pressure, serum potassium levels, and HbA1c. Results: There were 199 patients in Group A and 199 in Group B, matched 1:1 using propensity scores. UACR and blood pressure were significantly lower in Group A than in Group B. Geometric mean percent changes in UACR from baseline between the two groups were as follows: − 62.7% at 1 year (95% Confidence Interval (CI): − 91.0 to − 34.1%), − 48.9% at 2 years (95% CI: − 79.4 to − 19.3%), and − 63.8% at 3 years (95% CI: − 107.4 to − 20.2%). Additionally, the present study examined the impact of combining esaxerenone with SGLT2 inhibitors and GLP-1 receptor agonists and showed consistent effects on UACR irrespective of these medications. Esaxerenone slightly lowered eGFR with a low risk of hyperkalemia but did not adversely impact glucose metabolism. Conclusions: Esaxerenone exerted antihypertensive and antialbuminuric effects in patients with type 2 diabetes, diabetic kidney disease, and hypertension. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diabetology International is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
